MX2017013099A - Metodos para el tratamiento de trastornos inflamatorios. - Google Patents

Metodos para el tratamiento de trastornos inflamatorios.

Info

Publication number
MX2017013099A
MX2017013099A MX2017013099A MX2017013099A MX2017013099A MX 2017013099 A MX2017013099 A MX 2017013099A MX 2017013099 A MX2017013099 A MX 2017013099A MX 2017013099 A MX2017013099 A MX 2017013099A MX 2017013099 A MX2017013099 A MX 2017013099A
Authority
MX
Mexico
Prior art keywords
treatment
methods
inflammatory disorders
solvate
formula
Prior art date
Application number
MX2017013099A
Other languages
English (en)
Inventor
Tom Bert Paul Wigerinck Piet
Albert Eleutherius Van 't Klooster Gerben
Paul VANHOUTTE Frédéric
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1506229.2A external-priority patent/GB201506229D0/en
Priority claimed from GBGB1506419.9A external-priority patent/GB201506419D0/en
Priority claimed from GBGB1507113.7A external-priority patent/GB201507113D0/en
Priority claimed from GBGB1513345.7A external-priority patent/GB201513345D0/en
Priority claimed from GBGB1513993.4A external-priority patent/GB201513993D0/en
Priority claimed from GBGB1521543.7A external-priority patent/GB201521543D0/en
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2017013099A publication Critical patent/MX2017013099A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención describe compuestos de acuerdo con la fórmula (I): (ver Fórmula) o una sal farmacéut I del mismo, o un solvato o la sal de un solvato del mismo, composiciones farmacéuticas que comprenden al mismo, y métodos de tratamiento utilizando el mismo, para usarse en el tratamiento de condiciones inflamatorias, al administrar el compuesto de acuerdo con la fórmula I.
MX2017013099A 2015-04-13 2016-03-31 Metodos para el tratamiento de trastornos inflamatorios. MX2017013099A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1506229.2A GB201506229D0 (en) 2015-04-13 2015-04-13 Methods For the Treatment Of Inflammatory Disorders
GBGB1506419.9A GB201506419D0 (en) 2015-04-15 2015-04-15 Methods for the treatment of inflammatory disorders
GBGB1507113.7A GB201507113D0 (en) 2015-04-27 2015-04-27 Methods for the treatment of inflammatory disorders
GBGB1513345.7A GB201513345D0 (en) 2015-07-29 2015-07-29 Methods for the treatment of Inflammatory disorders
GBGB1513993.4A GB201513993D0 (en) 2015-08-07 2015-08-07 Methods for the treatment of inflammatory disorders
GBGB1521543.7A GB201521543D0 (en) 2015-12-07 2015-12-07 Methods for the treatment of inflammatory disorders
PCT/EP2016/057104 WO2016165953A1 (en) 2015-04-13 2016-03-31 Methods for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
MX2017013099A true MX2017013099A (es) 2018-01-26

Family

ID=55650412

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013099A MX2017013099A (es) 2015-04-13 2016-03-31 Metodos para el tratamiento de trastornos inflamatorios.

Country Status (12)

Country Link
US (1) US20180200257A1 (es)
EP (1) EP3283078A1 (es)
JP (1) JP2018511620A (es)
KR (1) KR20170134750A (es)
CN (1) CN107531694A (es)
AU (1) AU2016248728A1 (es)
BR (1) BR112017021583A2 (es)
CA (1) CA2982630A1 (es)
EA (1) EA201792264A1 (es)
MX (1) MX2017013099A (es)
SG (1) SG11201708181RA (es)
WO (1) WO2016165953A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019117562A (ru) 2016-11-10 2020-12-10 Галапагос Нв Соединения и их фармацевтические композиции для лечения воспалительных заболеваний
CN109111575B (zh) * 2018-05-23 2021-03-23 中山大学 一种金属-有机框架纳米颗粒的制备方法和应用
GB201808575D0 (en) * 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
US20220016165A1 (en) * 2020-02-20 2022-01-20 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
WO2022087313A1 (en) * 2020-10-22 2022-04-28 Progenity, Inc. Methods of treating and predicting non-response to anti-tnf treatment in subjects with gastrointestinal tract diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
HUE038878T2 (hu) 2012-06-22 2018-12-28 Galapagos Nv Aminotriazolopirimidin gyulladás kezelésében történõ alkalmazásra és gyógyászati készítményeik
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
KR20170134750A (ko) 2017-12-06
EA201792264A1 (ru) 2018-04-30
WO2016165953A1 (en) 2016-10-20
EP3283078A1 (en) 2018-02-21
JP2018511620A (ja) 2018-04-26
SG11201708181RA (en) 2017-11-29
AU2016248728A1 (en) 2017-10-12
CN107531694A (zh) 2018-01-02
US20180200257A1 (en) 2018-07-19
CA2982630A1 (en) 2016-10-20
BR112017021583A2 (pt) 2018-07-03

Similar Documents

Publication Publication Date Title
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12016501750A1 (en) Human plasma kallikrein inhibitors
PH12018500061A1 (en) Oxysterols and methods of use thereof
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MY182454A (en) Dihydropyrrolopyridine inhibitors of ror-gamma
SG10201811384TA (en) Mnk inhibitors and methods related thereto
PH12016502352A1 (en) Pharmaceutical composition
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2017002627A (es) Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2017002747A (es) Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak.